Revvity, Inc.

Revvity owns something genuinely valuable in its newborn screening and prenatal diagnostics franchise — government-mandated programs, multi-year revalidation switching costs, and regulatory clearances across dozens of jurisdictions that took decades to accumulate. The problem is that quality and price interact uncomfortably here: you're paying a premium multiple for a business whose ROIC hasn't yet demonstrated it can clear its own cost of capital, with a balance sheet that absorbed peak-cycle acquisition pricing and a life sciences segment that spent three years proving how thin its competitive differentiation actually is. The FCF yield provides some floor, but much of that cash flow is a non-cash amortization gift from overpaying for assets, not a signal of superior underlying economics. The trajectory is the most interesting part of the thesis. Instruments showing double-digit sequential growth after three consecutive years of decline, Signals software growing well ahead of plan, and the Eli Lilly partnership for Synthetica suggest the life sciences segment is turning from burden to contributor. If biotech funding normalizes as historical cycles suggest it will, Revvity sits at an unusual inflection where both segments recover simultaneously from depressed bases — a rare setup that the current conservative guidance doesn't reflect. The single biggest risk is China, and it deserves to be named plainly: management has now explicitly abandoned its prior forecast of a China immunodiagnostics recovery in the second half of next year. That's not a minor revision — it signals that domestic substitution and DRG pricing pressure are structural, not cyclical. A business with meaningful China revenue exposure, a leverage-heavy balance sheet, and a premium valuation multiple has very little cushion if that headwind compounds rather than stabilizes.